Human RCTPubMed ID: 36074393·2022

SURMOUNT-4: Tirzepatide Maintenance of Weight Loss

Wilding JPH, Batterham RL, Davies M, et al.

Lancet, 2022 · n = 431

Key finding

Continued tirzepatide maintained 25.2% weight loss at week 104 versus 4.9% with placebo (p<0.001); placebo group gained 11.2kg in 24 weeks.

Summary

Phase 3b maintenance trial showing sustained weight loss with continued tirzepatide and rapid weight regain after discontinuation.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

TirzepatideL5

An FDA-approved dual GIP/GLP-1 receptor agonist that has shown the highest weight loss results of any approved medication.

More research on Tirzepatide

Tirzepatide vs Semaglutide Once Weekly for Weight Management (SURMOUNT-5)

New England Journal of Medicine · 2024 · Human RCT

Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2)

The Lancet · 2023 · Human RCT

Tirzepatide for Weight Management after Lifestyle Intervention (SURMOUNT-3)

Nature Medicine · 2023 · Human RCT

SURPASS-4: Tirzepatide Cardiovascular Outcomes Trial

New England Journal of Medicine · 2023 · Human RCT

Tirzepatide Reduces Sleep Apnea Severity in Obesity

Sleep Medicine Reviews · 2023 · Human Pilot